Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2021
Reporting Period: Quarter ended September 30, 2021
Context: This filing serves to announce the company's financial results for the third quarter of 2021. The detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific numerical data. Consequently, the following metrics are not available in this excerpt:
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Margins: Not provided in text.
- Debt and Liquidity: Not provided in text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Guidance and Outlook: No specific forward-looking guidance or management commentary is included in the provided text.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information furnished is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 8, 2021) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an Emerging Growth Company (indicated as checked in the filing) and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol OCUL on the Nasdaq Global Market.
- Check for any updates to the company's pipeline or clinical trial results mentioned in the full press release, as this is a biopharmaceutical company.